Target family: Transmembrane guanylyl cyclases (type: catalytic_receptor)
Target: Guanylyl cyclase-C

Ligand: dolcanatide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.
Published in: World J Gastrointest Pharmacol Ther

Ligand: guanylin (Peptide)
Interaction type: Agonist
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: E. coli heat-stable enterotoxin (STa) (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.800000190734863 pKi
Reference (Journal): Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
Published in: Eur J Pharmacol

Ligand: indusatumab vedotin (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.869999885559082 pKd
Reference (Patent): Anti-GCC antibody molecules and related compositions and methods.

Ligand: linaclotide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA and EMA (2012)
Primary target: no
Median affinity: 8.380000114440918 pKi
Reference (Journal): Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
Published in: Eur J Pharmacol

Ligand: linaclotide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA and EMA (2012)
Primary target: yes
Median affinity: 8.90999984741211 pKi
Reference (Journal): Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
Published in: Eur J Pharmacol

Ligand: linaclotide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA and EMA (2012)
Primary target: yes
Median affinity: 8.90999984741211 pKi
Reference (Journal): Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation.
Published in: Curr Opin Mol Ther

Ligand: PF-07062119 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pKd
Reference (Journal): A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
Published in: Clin Cancer Res

Ligand: PF-07062119 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.760000228881836 pKd
Reference (Journal): A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
Published in: Clin Cancer Res

Ligand: PF-07062119 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.130000114440918 pKd
Reference (Journal): A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
Published in: Clin Cancer Res

Ligand: plecanatide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2017)
Primary target: no
Median affinity:  -
Reference (Journal): Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses.
Published in: Dig Dis Sci

Ligand: [125I]Sta (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.820000171661377 pKd
Reference (Journal): Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity.
Published in: Proc Natl Acad Sci USA

Ligand: uroguanylin (Peptide)
Interaction type: Agonist
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -